[Skip to Content]
[Skip to Content Landing]
Comment & Response
October 2015

Reporting of MABp1 for the Treatment of Psoriasis

Author Affiliations
  • 1Division of Dermatology, Baylor University Medical Center, Dallas, Texas
JAMA Dermatol. 2015;151(10):1143-1144. doi:10.1001/jamadermatol.2015.1684

To the Editor We were interested to read the report by Coleman et al1 in which they administered a novel interleukin (IL)-1α inhibitor, MABp1, to 8 patients with plaque psoriasis over 8 weeks in an open-label study. The issue of plaque psoriasis treatment is important because IL-1 inhibitors have shown some promise in treating generalized pustular psoriasis, an uncommon variant of psoriasis, which appears to be IL-1 mediated.2,3 Since all 5 biological therapies approved for use in moderate to severe plaque psoriasis—adalimumab, etanercept, infliximab, secukinumab, and ustekinumab—have better PASI 75 response rates (Psoriasis Area and Severity Index of ≥75) than the 13% improvement seen in the report on MABp1, it would seem that the statement that “the clinical responses…are encouraging”1(p556) should be tempered. By comparison, the PASI 75 response rates for adalimumab, etanercept, infliximab, ustekinumab, and secukinumab are 71% (16 weeks), 49% (12 weeks), 80% (10 weeks), 66% to 67% (12 weeks), and 77% to 82% (12 weeks), respectively.4,5